X
Access Company Profiles

Get business overview, business operations details specific to this market, products and services, latest developments and more...

Business Email

Select Companies

 

Colorectal Cancer Diagnostics and Therapeutics Companies

This report lists the top Colorectal Cancer Diagnostics and Therapeutics companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Colorectal Cancer Diagnostics and Therapeutics industry.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Colorectal Cancer Diagnostics and Therapeutics Top Companies

  1. Epigenomics

  2. Abbott Laboratories

  3. Roche

  4. Novigenix

  5. Amgen

*Disclaimer: Top companies sorted in no particular order

Colorectal Cancer Diagnostics and Therapeutics Market Major Players

Colorectal Cancer Diagnostics and Therapeutics Market Concentration

Colorectal Cancer Diagnostics and Therapeutics  Market Concentration

Colorectal Cancer Diagnostics and Therapeutics Company List

                            • Abbott Laboratories

                            • Amgen Inc.

                            • Clinical Genomics

                            • EDP Biotech

                            • Epigenomics AG

                            • F. Hoffmann-La Roche AG

                            • Novigenix SA

                            • Quest Diagnostics

                            • Sanofi SA

                            • Siemens Healthineers

                            • VolitionRX


                        Specific to Colorectal Cancer Diagnostics and Therapeutics Market
                        Need More Details On Market Players And Competitors?
                        Download PDF

                        Colorectal Cancer Diagnostics and Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)